Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy
Authors:
- Huldrych F. GünthardHGHuldrych F. Günthard
- Joseph K. WongJWJoseph K. Wong
- Richard T. D'AQuilaRDRichard T. D'AQuila
- Victoria A. JohnsonVJVictoria A. Johnson
- Daniel R. KuritzkesDKDaniel R. Kuritzkes
- Douglas D. RichmanDRDouglas D. Richman
- Andrew J. Leigh BrownABAndrew J. Leigh Brown
- 1 January 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (1) , 31-36
Abstract
To determine whether analysis of sequence variation in reverse transcriptase at baseline can explain differences in response to combination antiretroviral therapy. Amino acid sequences of reverse transcriptase obtained from baseline isolates from 55 patients included in a trial of zidovudine and didanosine versus zidovudine/didanosine/nevirapine (ACTG241) were analysed. Simple and multiple linear regression were used to determine the relationship between numbers and identity of mutations at baseline and virological response after 8 and 48 weeks. Numbers of baseline zidovudine resistance mutations were predictive of short-term response (week 8). Amino acid identity at position 215 explained > 20% of the variation in response at week 8, but less at week 48. Multiple regression identified the combinations: 215 + 44 and 41 + 202, each of which explained about 30% of the variation in week 8 response. A model incorporating amino acids 214 + 215 + 60 + 202 + baseline viral load explained > 40% of the variation in response at week 48. Unexpectedly, the mutant combination 60I + 215Y/F responded threefold better than 60V + 215Y/F over 48 weeks. Use of clinical data to analyse virological response to combination therapy has revealed effects of baseline amino acid mutations at sites not previously identified as being important in antiretroviral resistance. Predictors of long-term responses were different from those involved in the short term and may require more complex analysis.Keywords
This publication has 23 references indexed in Scilit:
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic ResponseAnnals of Internal Medicine, 1997
- Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level withRisk of Clinical Progression in Patients with Advanced InfectionThe Journal of Infectious Diseases, 1996
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- Response of HIV RNA to didanosine as a predictive marker of survivalAIDS, 1995
- Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistanceJournal of General Virology, 1994
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.Proceedings of the National Academy of Sciences, 1993
- Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.Proceedings of the National Academy of Sciences, 1991